An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

Bruce Willis is alive. Last week, a death hoax of Bruce Willis have circulated, however, his representatives confirmed on March 7, Saturday that the news is fabricated. "He joins the long list of celebrities who have been victimized by this hoax. He's still alive and well, stop believing what you see on the Internet," his official representative stated. In fact, in the coming 19th of the month, The Die Hard star will turn 71. Bruce Willis is currently at his home with his family and is living with frontotemporal dementia. He is continuing into third year living with the condition.

Bruce Willis Health Update: Time Line Of Diagnosis

In March 2022, fans were shocked by a family statement revealing Willis had been diagnosed with aphasia. The announcement was brief but clear: the condition was affecting his cognitive abilities and making it impossible for him to continue his acting career. However, aphasia was just one piece of the puzzle.

By February 2023, a more specific diagnosis emerged. The Willis family confirmed Bruce was dealing with frontotemporal dementia, a degenerative condition that often begins with language difficulties and eventually affects decision-making, emotional regulation, and behavior.

Read: Bruce Willis Health Update: A Diagnostic Timeline From Aphasia To Dementia

"Challenges with communication are just one symptom of the disease Bruce faces," the family shared at the time, emphasizing that the condition affects far more than speech.

Unlike Alzheimer’s disease, FTD tends to strike earlier, often in one’s 50s or 60s—and can progress quickly. It affects the frontal and temporal lobes of the brain, areas associated with language, behavior, and executive function. Currently, there is no cure.

Read: Bruce Willis’ Wife Emma Says He Is Unaware of His Dementia Diagnosis

What Is Frontotemporal Dementia?

Frontotemporal dementia is a less prevalent type of dementia that mainly occurs in the frontal and temporal lobes of the brain. It tends to affect behavior, personality, language, and movement more than memory, particularly in its initial stages.

In contrast to Alzheimer's, which generally strikes older individuals, FTD can hit at an earlier age—sometimes as young as 40. The symptoms can range from changes in personality, emotional flatness, or the inability to show empathy to impulsiveness, so it is especially hard for spouses and children to cope.

Emma's case illustrates how abrupt and disrupting this diagnosis can be—not only for the patient but for caregivers as well.

Whereas Bruce Willis' diagnosis hit global headlines, the mental toll taken by Emma, his caregiver, was largely in the background—until she decided to come forward.

Caregiving is a respectable position, but it's also a challenging and thankless one. For those who are caring for loved ones with dementia or other chronic illnesses, the stress of "keeping it all together" can result in a condition called caregiver burnout.

"Caring for someone is the most intimate and demanding work of love," Emma explained, "but when you're not noticed or supported, it begins to undermine your health—mentally and physically."

Meghalaya health officials have asked locals to avoid crowded places after two Agniveer trainees have died of suspected meningococcal bacterial infection at a training centre in Shillong in February.

While the first trainee died at the Military Hospital in the Assam Regimental Centre (ARC), the other died on February 23. The remaining 28 trainees have been placed in quarantine.

Joram Beda, Health and Family Welfare Commissioner-Secretary, said the East Khasi Hills District Surveillance Unit has initiated an active epidemiological investigation, including contact tracing, isolation of close contacts, and fumigation, which has been carried out in and around the affected military facility.

“Case investigation, contact tracing, laboratory review, and surveillance strengthening measures are currently underway,” the official advisory read.

The Health and Family Welfare Department also said the State Surveillance Unit has been activated and a detailed epidemiological investigation is currently underway. Authorities further added that surveillance has been strengthened not just within the Army training establishment but also in surrounding areas as a precaution.

The state government has asked people to avoid crowded areas, wear masks in crowded places, practise good respiratory hygiene and wash their hands regularly with soap and sanitiser.

It also asked residents to report to the nearest medical facility in cases of sudden high fever, headache, vomiting, rapidly spreading purpuric (purple-coloured spots or patches) rashes, pale limbs at a later stage, and circulatory collapse, shock, and multi-organ failure.

What Is Meningococcal Disease?

How Does Meningococcal Disease Spread?

Meningococcal bacteria are transmitted through respiratory droplets, by coughing, sneezing, kissing, or sharing food and drinks. The greatest risk occurs between people with extended, close contact, such as family members and sexual partners. Prolonged riding in enclosed vehicles, such as buses, planes, with the infected person, also greatly increases risk.

CDC states that infants below one year, adolescents 16–23 years old, immunocompromised patients, and residents of communal environments are at greatest risk.

Early Symptoms of Meningococcal Disease

The infection at first presents a nonspecific viral illness, but can worsen suddenly. Adults must be aware of the following signs:

• Fever, headache, stiff neck – classic symptoms of meningitis
• Red spots or rash – typically seen as pinpricks or larger bruise-like patches, a sign of blood vessel involvement
• Nausea, vomiting, photophobia (light sensitivity)
• Confusion, lethargy, rapid breathing, seizures – signs of severe progression
• Neck stiffness and changed mental status, usually with fever

In the most severe cases, sepsis, exhaustion, coldness of extremities, and coma may ensue, all necessitating immediate medical intervention. Shockingly, worsening can happen within 12 hours of the onset of symptoms.

Diagnosis and Treatment of Meningococcal Disease

The gold-standard diagnosis for invasive meningococcal disease involves a combination of blood cultures and cerebrospinal fluid (CSF) analysis obtained through lumbar puncture.

However, in cases where increased intracranial pressure is suspected, performing a lumbar puncture may need to be delayed to avoid complications. Additionally, polymerase chain reaction (PCR) testing plays a crucial role in rapidly identifying the infection, particularly when prior antibiotic treatment may interfere with traditional culture results.

IMD survivors develop severe complications: hearing loss, neurological injury, kidney failure, or limb amputation by necrosis. Unfortunately, natural infection does not offer absolute lifelong immunity; recurrence, although infrequent, can occur, warranting immune deficiency assessments.

Vaccination is the best protection. Vaccines protect against several serogroups (A, B, C, W, Y, X) and are universally advised, particularly among adolescents, travelers, and those at risk.

Wegovy maker Novo Nordisk has ended its legal dispute with the Hims & Hers Health platform, according to a media report.

The two companies are likely to partner and sell the blockbuster obesity drug Wegovy together on the Hims & Hers Health platform, Bloomberg News reported.

Market analysts have expressed surprise on the move, as both Novo and Hims have been previously engaged in legal battle over Wegovy.

“There is no other way to describe the Hims news as both a surprise and an unabashed positive for Hims' stock,” Leerink Partners analyst Michael Cherny was quoted as saying in a note to clients.

A Novo spokesperson said in an emailed statement that the company is "always in conversation with companies that can help improve patient access to FDA-approved medicines".

The Dispute Between Novo and Hims

In February, Novo sued Hims for launching a similar version of its new Wegovy weight-loss pill for $49.

The Danish drugmaker accused Hims of patent infringement on Semaglutide -- the active ingredient behind its best-selling medications Ozempic and Wegovy.

Semaglutide is popularly known for weight loss , but is also effective for diabetes and is used primarily for that.

The US Food and Drug Administration (FDA) had also threatened action against Hims.

Last year, Novo had to end a short-lived agreement to sell Wegovy over Him's marketing tactics and continued sales of copycat versions of Wegovy.

Recently, the FDA has signaled plans to crack down on the proliferation of copycat, or compounded, weight-loss drugs.

Wegovy And Ozempic To Cost Less In 2027

Currently, Wegovy injections and pills cost $1,349.02 a month, whereas Ozempic and Rybelus cost $1,027.51, Novo told PEOPLE.

Individuals with commercial insurance pay $25 a month, whereas those using cash pay between $149 to $499. Patients on Medicare will pay $274 per month.

Late in February, Novo Nordisk announced it would slash the price for all doses:

• The list price of Wegovy injections and the new Wegovy pill will be cut in half
• Ozempic injections will be cut by 35 percent
• The semaglutide tablet Rybelsus will now cost $675 a month

"There are more than 100 million people living with obesity and over 35 million with type 2 diabetes and, and for some, list price has been a real barrier to access and affordability," Jamey Millar, Executive Vice President, US Operations of Novo Nordisk Inc., was quoted as saying to PEOPLE.

Indian Drugmakers Rush For Generic Weight Loss Drugs

Meanwhile, amid the patent expiration of semaglutide, several pharma companies in India are planning big launches of Wegovy's generic versions.

Several leading drugmakers have already secured regulatory approval or recommendations to produce and market generic versions of the weight loss drugs in the country.

Hyderabad-based Dr. Reddy's already applied for a trademark with the brand name Obeda and a logo.

Other companies like Sun Pharma, Zydus Lifesciences, and Nacto Pharma are also entering the rat race of launching multiple generic versions to make the treatment more affordable for patients with obesity and weight-related health risks.

Sun Pharma also announced the plans for "day-one" launches of generic prefilled pens.